Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP

Biochimie

Volumn 93, Issue 4, 2011, Pages 669-677

  Dejda, Agnieszka ^a,b   Bourgault, Steve ^a,b,d   Doan, Ngoc Duc ^a,b   Létourneau, Myriam ^a,b   Couvineau, Alain ^c   Vaudry, Hubert ^b,d   Vaudry, David ^b,d   Fournier, Alain ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ DE ROUEN   (France)

Author keywords

Binding sites; G protein coupled receptors; PAC1 receptor; Photoaffinity labeling; Pituitary adenylate cyclase activating polypeptide; Two domain model

Indexed keywords

4 BORONOPHENYLALANINE; AMINO TERMINAL TELOPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; IODINE 125; NORLEUCINE; PARA BENZOYL PHENYLALANINE; PROTEINASE; STEARYL NORLEUCINE 17; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; COVALENT BOND; HUMAN; NONHUMAN; PHOTOAFFINITY LABELING; PHOTOSENSITIVITY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION;

AMINO ACID SEQUENCE; ANIMALS; BENZOPHENONES; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HUMANS; IODINE ISOTOPES; MOLECULAR SEQUENCE DATA; PHENYLALANINE; PHOTOAFFINITY LABELS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I;

CRICETULUS GRISEUS;

EID: 79952448783     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.12.010     Document Type: Article

References (34)

1. M.C. Lagerström, and H.B. Schiöth Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discov. 7 2008 339 357
2. S.M. Foord Receptor classification: post genome Curr. Opin. Pharmacol. 2 2002 561 566
3. S.R. Hoare Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors Drug Discov. Today 10 2005 417 427 (Pubitemid 40450272)
4. B.D. Green, V.A. Gault, F.P. O'Harte, and P.R. Flatt Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents Curr. Pharm. Des. 10 2004 3651 3662 (Pubitemid 39386580)
5. M. Girotra, M.R. Rubin, and J.P. Bilezikian Anabolic skeletal therapy for osteoporosis Arq. Bras. Endocrinol. Metabol. 50 2006 745 754 (Pubitemid 44786010)
6. F. Holsboer, and M. Ising Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists Eur. J. Pharmacol. 583 2008 350 357
7. M. Dong, P.C. Lam, F. Gao, K. Hosohata, D.I. Pinon, P.M. Sexton, R. Abagyan, and L.J. Miller Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor Mol. Pharmacol. 72 2007 280 290 (Pubitemid 47124108)
8. M. Dong, P.C. Lam, D.I. Pinon, P.M. Sexton, R. Abagyan, and L.J. Miller Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding Mol. Pharmacol. 74 2008 413 422
9. R.C. Gensure, T.J. Gardella, and H. Jüppner Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking J. Biol. Chem. 276 2001 28650 28658
10. M. Dong, D.I. Pinon, R.F. Cox, and L.J. Miller Importance of the amino terminus in secretin family G protein-coupled receptors. Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor J. Biol. Chem. 279 2004 1167 1175 (Pubitemid 38082639)
11. Q. Chen, D.I. Pinon, L.J. Miller, and M. Dong Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes J. Biol. Chem. 284 2009 34135 34144
12. Y.V. Tan, A. Couvineau, S. Murail, E. Ceraudo, J.M. Neumann, J.J. Lacapre, and M. Laburthe Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling J. Biol. Chem. 281 2006 2792 2798
13. E. Ceraudo, Y.V. Tan, P. Nicole, A. Couvineau, and M. Laburthe The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor J. Mol. Neurosci. 36 2008 245 248
14. A. Dejda, V. Jolivel, S. Bourgault, T. Seaborn, A. Fournier, H. Vaudry, and D. Vaudry Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases J. Mol. Neurosci. 36 2008 26 37
15. D. Vaudry, C. Rousselle, M. Basille, A. Falluel-Morel, T.F. Pamantung, M. Fontaine, A. Fournier, H. Vaudry, and B.J. Gonzalez Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death Proc. Natl. Acad. Sci. U S A 99 2002 6398 6403 (Pubitemid 34493323)
16. H. Ohtaki, T. Nakamachi, K. Dohi, Y. Aizawa, A. Takaki, K. Hodoyama, S. Yofu, H. Hashimoto, N. Shintani, A. Baba, M. Kopf, Y. Iwakura, K. Matsuda, A. Arimura, and S. Shioda Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6 Proc. Natl. Acad. Sci. U S A 103 2006 7488 7493 (Pubitemid 43727860)
17. N. Aubert, D. Vaudry, A. Falluel-Morel, A. Desfeux, C. Fisch, P. Ancian, S. de Jouffrey, J.F. Le Bigot, A. Couvineau, M. Laburthe, A. Fournier, V. Laudenbach, H. Vaudry, and B.J. Gonzalez PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway Neurobiol. Dis. 32 2008 66 80
18. D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B.K. Chow, H. Hashimoto, L. Galas, and H. Vaudry Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery Pharmacol. Rev. 61 2009 283 357
19. S. Bourgault, D. Vaudry, A. Dejda, N.D. Doan, H. Vaudry, and A. Fournier Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective peptide Curr. Med. Chem. 16 2009 4462 4480
20. P. Robberecht, P. Gourlet, P. De Neef, M.C. Woussen-Colle, M.C. Vandermeers-Piret, A. Vandermeers, and J. Christophe Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclaseactivating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21 Mol. Pharmacol. 42 1992 347 355 (Pubitemid 23026170)
21. S. Bourgault, D. Vaudry, L. Guilhaudis, E. Raoult, A. Couvineau, M. Laburthe, I. Ségalas-Milazzo, H. Vaudry, and A. Fournier Biological and structural analysis of truncated analogs of PACAP27 J. Mol. Neurosci. 36 2008 260 269
22. S Proc. Natl. Acad. Sci. U S A 104 2007 7875 7880 (Pubitemid 47185844)
23. S. Bourgault, D. Vaudry, B. Botia, A. Couvineau, M. Laburthe, H. Vaudry, and A. Fournier Novel stable PACAP analogs with potent activity towards the PAC1 receptor Peptides 29 2008 919 932
24. Y.J. Cao, and G. Gimpl A constitutively active pituitary adenylate cyclase activating polypeptide (PACAP) type I receptor shows enhanced photoaffinity labeling of its highly glycosylated form Biochim. Biophys. Acta 1548 2001 139 151 (Pubitemid 32622829)
25. S. Matsuzaki, and M. Tohyama Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia Expert Opin. Ther. Targets 12 2008 1097 1108
26. R. Hashimoto, H. Hashimoto, N. Shintani, K. Ohi, H. Hori, O. Saitoh, A. Kosuga, M. Tatsumi, N. Iwata, N. Ozaki, K. Kamijima, A. Baba, M. Takeda, and H. Kunugi Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder Neurosci. Lett. 468 2010 300 302
27. S. Bourgault, D. Vaudry, I. Ségalas-Milazzo, L. Guilhaudis, A. Couvineau, M. Laburthe, H. Vaudry, and A. Fournier Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor J. Med. Chem. 52 2009 3308 3316
28. Y.J. Cao, E. Kojro, G. Gimpl, M. Jasionowski, F. Kasprzykowski, L. Lankiewicz, and F. Fahrenholz Photoaffinity labeling analysis of the interaction of pituitary adenylate-cyclase-activating polypeptide (PACAP) with the PACAP type I receptor Eur. J. Biochem. 244 1997 400 406 (Pubitemid 27110741)
29. E. Ceraudo, S. Murail, Y.V. Tan, J.J. Lacapre, J.M. Neumann, A. Couvineau, and M. Laburthe The vasoactive intestinal peptide (VIP) alpha-helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics Mol. Endocrinol. 22 2008 147 155
30. A. Couvineau, E. Ceraudo, Y.V. Tan, and M. Laburthe VPAC1 receptor binding site: contribution of photoaffinity labeling approach Neuropeptides 44 2010 127 132
31. A. Bisello, A.E. Adams, D.F. Mierke, M. Pellegrini, M. Rosenblatt, L.J. Suva, and M. Chorev Parathyroid hormone-receptor interactions identified directly by photocross-linking and molecular modeling studies J. Biol. Chem. 273 1998 22498 22505 (Pubitemid 28399816)
32. Q. Chen, D.I. Pinon, L.J. Miller, and M. Dong Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor. A region critical for biological activity J. Biol. Chem. 285 2010 24508 24518
33. J. Kyte, and R.F. Doolittle A simple method for displaying the hydropathic character of a protein J. Mol. Biol. 157 1982 105 132
34. G.E. Tusnady, and I. Simon The HMMTOP transmembrane topology prediction server Bioinformatics 17 2001 849 850 (Pubitemid 32970487)